Ronald Bukowski, MD
Enriched profileEmeritus Staff, Cleveland Clinic Taussig Cancer Institute; Director, Bukowski Consulting, LLC · Cleveland Clinic Taussig Cancer Institute (Emeritus)
Ronald Bukowski is Emeritus Staff, Cleveland Clinic Taussig Cancer Institute; Director, Bukowski Consulting, LLC at Cleveland Clinic Taussig Cancer Institute (Emeritus). ClinicalTrials.gov lists 6 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 2 Sept 2026
Ronald Bukowski, MD, is Emeritus Staff, Cleveland Clinic Taussig Cancer Institute. The public record shows 616 publications with 45,177 citations (h-index 90), centered on Kidney Cancer / RCC, Kidney Neoplasms, Melanoma. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 9 companies, 6 NIH-funded awards (1985–1994).
- Top research focus: Kidney Cancer / RCC
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 9 companies
Generated from the cited public record · current as of 2 Sept 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 2 Sept 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- Docetaxel and Temozolomide in Treating Patients With Metastatic Cancer
Sponsor: The Cleveland Clinic
- Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer
Sponsor: The Cleveland Clinic
- Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer
Sponsor: Case Comprehensive Cancer Center
Industry payments
Updated 2 Sept 2026
9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20257 payments$28,230openpaymentsdata.cms.gov ↗
- Janssen Research & Development, LLCProgram year20256 payments$22,950openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20255 payments$18,950openpaymentsdata.cms.gov ↗
NIH funding
Updated 2 Sept 2026
6 NIH research awards on record, funded 1985–1994 per NIH RePORTER. The latest:
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
British Journal of Cancer
2015 - Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
Journal of Clinical Oncology
2012
Online presence
Updated 2 Sept 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
kidneycancer.org/spotlight-dr-ronald-m-bukowski
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →kidneycancer.org ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 2 Sept 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
- Board Certified: Hematology
Internal Medicine, Medical Oncology (American Board of Medical Specialties)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prnewswire.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →kidneycancer.org ↗
Secondary affiliations
appointments beyond the home institution- Professor of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prnewswire.com ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Peter Carroll, MD
University of California, San Francisco